Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-07-29
2000-07-18
Caputa, Anthony C.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
514 12, 424 852, 530350, 530351, A61K 3800, A61K 3820
Patent
active
060907754
DESCRIPTION:
BRIEF SUMMARY
FIELD OF THE INVENTION
This invention relates to a method for treatment of neurological conditions and to compositions and products useful for such treatment.
BACKGROUND OF THE INVENTION
Neurological conditions pose serious clinical problems, as their effects are severe and long-lasting but little is known of any really effective means for curing or even controlling them.
There is, therefore, a considerable need for some treatment for such conditions.
SUMMARY OF THE PREFERRED EMBODIMENTS
According to a first aspect of the present invention there is provided the use of a compound which prevents, inhibits or modifies the action of interleukin-1 as an active agent for the treatment of conditions of neurological degeneration.
According to a second aspect of the present invention there is provided a formulation adapted for the use as defined in the previous paragraph, comprising an active agent as defined therein dispersed or dissolved in a pharmaceutically acceptable carrier (solvent or diluent), especially in water or an aqueous medium, especially in normal saline (an isotonic solution of sodium chloride in water).
According to a third aspect of the present invention there is provided a method of treating neurological degenerative conditions in a human or animal patient comprising administration as an active agent a compound which prevents, inhibits or modifies the action of interleukin-1.
Other objects, features and advantages of the present invention will become apparent to those skilled in the art from the following detailed description. It is to be understood, however, that the detailed description and specific examples, while indicating preferred embodiments of the present invention, are given by way of illustration and not limitation. Many changes and modifications within the scope of the present invention may be made without departing from the spirit thereof, and the invention includes all such modifications.
BRIEF DESCRIPTION OF THE DRAWINGS
The invention may be more readily understood by referring to the accompanying drawings in which
FIGS. 1A-B illustrate the effect of IL-1 receptor antagonist protein (IL-1 ra) on neuronal damage after cerebral ischemia. (B) The lower panel shows the volume of damage (mm.sup.3, computed from the volume under the curve for upper panel, A). Mean.+-.SEM, one way ANOVA, *P<0.05, and
FIGS. 2A-B illustrate the effect of IL-1 receptor antagonist protein on NMDA receptor mediated neuronal damage. (A) Upper panel shows the area of damage (mm.sup.2) and (B) the lower panel shows the lesion volume (mm.sup.3, computed from the volume under the curve for upper panel). Mean.+-.SEM, unpaired Students t-test, *P<0.001.
DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS
Interleukin-1 is commonly referred to as "IL-1".
The active agent thus defined has the effect of protecting neurons from adverse effects, i.e. neuro-degeneration.
The active agent used may be in a variety of forms, for example a naturally occurring product or one produced by artificial or synthetic methods, for example a genetically engineered form. Particularly suitable is interleukin-1 receptor antagonist protein (conveniently referred to as "IL-1ra"), particularly recombinant IL-1 ra. It is also possible to use analogues of IL-1 ra, as well as derivatives and fragments thereof (and analogues of these compounds).
Our treatment is useful for a variety of conditions of neurological degeneration, however caused, though the means by which the active agent we specify here works is not yet clearly understood. It is believed that it is probably by blocking the action of interleukin-1. The invention is especially applicable to treatment of the neurons in the brain, periphery and spinal chord.
Cerebral lesions in several chronic neurodegenerative conditions (e.g. Alzheimer's disease (AD) and Down's Syndrome) are known to be associated with the formation of beta-amyloid (beta-AP), apparently due to abnormal metabolism of beta-amyloid precursor protein (beta-APP) with consequent deposition of beta-AP.
IL-1 has b
REFERENCES:
Rudinger In "Peptide Hormones" (Jun. 1976) ed. J.A. Parsons, University Park Press, Baltimore, pp. 1-7.
Lieberman, International Rev. of Neurobiology 14 (1971) 49-124.
Jackowski, British J. of Neurosurgery 9 (1995) 303-317.
Hefti et al., Neurobiol. of Aging 9 (1988) 689-690.
Marx, Science 255 (1992) 688-689.
Meldrum et al. TIPS 11 (1990) 379-387.
The Merck Manual--14th edition (1982) p. 1414.
Guenard et al J. Neurosci. Bes. 29 396-400 (1991).
Relton et al J. Physiol. 452 122P (1992).
Relton et al Brain Res. Bull 29 243-246 (1992).
Jacobs et al J. Immunol. 146 2983-9 (1991).
Stockman et al Biochemistry 31 5237-45 (1992).
Dana Giulian, et al., "Interleukin 1 of the central nervous system is produced by ameboid microglia", J. Exp. Med. The Rockerfeller University Press. vol. 164, Aug. 986, pp. 594-604.
Dmitry Goldgaber, et al., "Interleukin 1 regulates synthesis of amyloid .beta.-protein precursor mRNA in human endothelial cells", Proc. Natl. Acad. Sci. USA. vol. 86, pp. 7606-7610, Oct. 1989.
W. Sue T. Griffin, et al., "Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease", Proc. Natl. Acad. Sci. USA, vol. 86, pp. 7611-7615, Oct. 1989.
Masabumi Minami, et al., "Convulsants induce interleukin 1.beta. messenger RNA in rat brain", Biochemical and Biophysical research communications, vol. 171, No. 2, 1990, Sep. 14, 1990, pp. 832-837.
Jane K. Relton, et al., "Lipocorin-1 is an endogenous inhibitor of ischemic damage in the rat brain", J. Exp. Med The Rockerfeller University Press, vol. 174, Aug. 1991, pp. 305-310.
Nancy Jane Rothwell, "Functions and mechanisms of interleukin 1 in the brain", Elsevier Science Publishers Ltd. vol. 12, Nov. 1991, pp. 430-436.
Dana Giulian, et al., "Interleukin-1 injected into mammalian brain stimulates astrogliosis and Neovascularization", The Journal of Neuroscience, Jul. 1988, 8(7) 2485-2490.
International Search Report, Pat. Appl. No. PCT/GB92/02023, Mar. 5, 1993.
A. Lachaux, "Les antagonistes du recepteur de L'interleukine-1", Pediatrie, vol. 46, No. 10, 1991, p.
D. B. Carter, "Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein", Nature, vol. 344, Apr. 12, 1990, pp. 633-637.
F. Carey, et al., "Lipocortin 1 fragment modifies pyrogenic actions of cytokines in rats", American Physiological Society, 1990.
Jane K. Relton, et al., "Lipocortin-1 is an Endogenous Inhibitor is Ischemic Damage in the Rat Brain", J. Exp. Med. The Rokefeller University Press, vol. 174, Aug. 1991.
Charles H. Hannum, et al., "Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor", Nature, vol. 343, Jan. 25, 1990.
Stephen P. Eisenberg, et al., "Primary structure an functional expression from complementary DNA of a human interleukin-1 receptor antagonist", Nature, vol. 343, Jan. 25, 1990.
Roberts Gareth
Rothwell Nancy Jane
Caputa Anthony C.
Hayes Robert C.
The Victoria University of Manchester
LandOfFree
Treatment of neurological conditions by an interleukin-1 inhibit does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of neurological conditions by an interleukin-1 inhibit, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of neurological conditions by an interleukin-1 inhibit will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2037135